G

Gesynta Pharma AB

14 employees

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

Basic info

Industry

pharmaceutical manufacturing

Sectors

Health Care
Pharmaceutical
Biopharma

Date founded

2017

Funding rounds raised

Total raised

$21M

from 4 investors over 4 rounds

G

Gesynta Pharma AB raised $21M on July 7, 2020

Investors: Linc AB, Hadean Ventures and Industrifonden

G

Gesynta Pharma AB raised $6.7M on April 5, 2019

Investors: Industrifonden

FAQ